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Abstract
A fully automated, high-throughput method was developed to profile the fatty acids of phospholipids from human
plasma samples for application to a large epidemiological sample set (n > 25,000). We report here on the data
obtained for the quality-control materials used with the first 860 batches, and the validation process used. The
method consists of two robotic systems combined with gas chromatography, performing lipid extraction,
phospholipid isolation, hydrolysis and derivatization to fatty-acid methyl esters, and on-line analysis. This is the first
report showing that fatty-acid profiling is an achievable strategy for metabolic phenotyping in very large
epidemiological and genetic studies.
Background
The association between the fatty-acid composition of the
diet and the development of various diseases has been the
subject of many epidemiological studies. It is also recog-
nized that gene-diet interactions may play an important
role in the development of chronic disease. The ability to
study these associations with sufficient certainty relies on
very large sample sets. Most past studies used fatty-acid
composition information derived from self-reported diet-
ary questionnaires, which can be prone to substantial mea-
surement error and may contribute to inconclusive results
across different studies, for example the association
between specific fatty acids and type 2 diabetes [1-4]. This
has led to the search for nutritional biomarkers for fatty
acids that could be used to validate the data obtained by
dietary questionnaires, or to be used to investigate gene-
diet interactions directly. Fatty-acid biomarkers are
regarded to provide an objective measurement of some
types of dietary fat intake [5], and epidemiological studies
can use fatty acids measured in several blood lipid pools as
nutritional biomarkers to investigate the association with
disease conditions, such as type 2 diabetes [6,7]. However,
the lack of published methods to profile fatty acids in very
large sample sets has hampered efforts to combine meta-
bolic information with genetic data to study gene-diet
interaction in disease development. Although several stu-
dies have combined genetic data with metabolic profiling,
most of these studies did not focus on gene-diet interac-
tions in relation to disease development, used only data
from healthy individuals [8,9], did not have sufficient
power to allow investigation of the association with diet
[10], or did not find an effect of diet on the association
between fatty acid levels and genes[11].
The application of nutritional biomarkers in large-scale
epidemiological studies can be possible only if the analysis
of the biomarkers is sufficiently fast, relatively cheap,
robust and precise. We decided to to develop an auto-
mated method specifically for fatty-acid profiling of the
plasma-phospholipid fraction, which would provide the
molar percentage of each of the fatty acids in line with
previous reports [5-7,11]. This automated method com-
prised the following steps: 1) extraction of total lipids from
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plasma samples; 2) isolation of the phospholipid fraction
from the total lipids by solid-phase extraction (SPE); 3) a
combined hydrolysis and derivatization step to convert the
phospholipids into free fatty acids and then methylate
these to form the more volatile fatty-acid methyl esters
(FAME); 4) FAME extraction and 5) the final gas chroma-
tographic separation combined with flame ionization
detection. The chromatographic separation was developed
to resolve different geometric isomers of particular fatty
acids such as cis and trans oleic acid (C18:1n9) in an
acceptable chromatographic run time. However, these
complex sample -preparation procedures for fatty-acid
analysis are time-consuming and allow the possibility of
errors when performed manually.
Several groups have reported the development of
automated or high-throughput fatty-acid profiling of
human plasma samples [12,13]. However, none of these
methods automated both the phospholipid extraction
and FAME derivatization and applied this to very large
sample sets [14]. Since fatty-acid profiling by gas chro-
matography (GC) using FAME derivatization first
became established, improvement in sample throughput
has been sought, and this is still an active area of
research [15,16]. This study is the first report of an
automated method for fatty-acid analysis of the phos-
pholipid fraction of human plasma, which includes both
phospholipid extraction and FAME derivatization, and
has been successfully applied to date to more than
28,000 samples of the InterAct project (detailed infor-
mation about the subjects can be found in the cohort
description [17]). The InterAct project aims to measure
the plasma-phospholipid fatty-acid profile in 12,403 veri-
fied diabetes cases and 16,154 subcohort participants
within the European Prospective Investigation into Can-
cer study, in eight European countries [17]. Achieving
this aim is not practical with standard manual sample
preparation [6], therefore, our aim was to develop a
completely automated, high-throughput method that
would give results comparable with those of previous
studies that used manual methods. This automated
method should enable conduct of large epidemiological
studies such as the InterAct project, covering 28,000
samples [17].
In this report, we focus on aspects of method develop-
ment, validation, and quality control (QC). The method
has been validated on different batches of QC samples.
The actual analysis is carried out on three parallel sys-
tems, each consisting of two robots and a GC system,
which work in parallel using exactly the same equip-
ment and methods. This system is unique in its ability
to run very large sample sets, and in this paper, we
report the method validation and the results obtained
for the QC material used for the first 860 batches ana-
lyzed by the method, which demonstrates the ability of
the apparatus to maintain the same quality over many
samples using the three independent systems. This
report is a quintessential first step in the process of
applying metabolic phenotyping to study gene-diet inter-
action in the development of type 2 diabetes [17].
Results and Discussion
Comparison of conventional with automated sample
preparation
Comparison experiments were conducted using 52 identi-
cal QC2 (horse plasma) samples divided randomly into
two groups. The aim of this experiment was not to revali-
date the approach of using SPE extraction in combination
FAME analysis by GC to determine the fatty-acid compo-
sition of the phospholipid fraction; this approach, which
can have qualitative and quantitative limitations, has
already been widely used in nutritional and epidemiologi-
cal studies [5]. Our aim was to determine if the automated
method could deliver results that are comparable with
manual methods. Extraction of total lipids and isolation of
the phospholipid fraction were performed by both conven-
tional (n = 26) and automated (n = 26) methods. The
mean, standard deviation (SD) and percentage coefficient
of variation (%CV) of 19 major phospholipid fatty acids
(for peaks over 0.1%, horse-plasma phospholipids are less
diverse than human plasma phospholipids) in the QC2
samples were calculated from the two methods (Figure 1;
see Additional file 1, Table S1). The mean values for the
19 fatty acids obtained with the automated method
showed high correlation (r = 0.9999) with those performed
with the manual method, indicating a significant linear
relationship (P < 0.001) (Figure 1A). However, the preci-
sion of the automated method was better than that of the
manual method with SDs of less than or equal to those of
the manual method (Figure 1B). The Bland-Altman plot
showed good agreement between the two methods, with
an average difference of 0.03%. shows The automated
method had smaller %CV values than those of the conven-
tional manual method for most of the fatty acids, indicat-
ing that the analytical precision was improved by the use
of the newly developed automated method (see Additional
file 1, Table S1).
Method validation
The flame ionization detector (FID) is a sensitive detector
for FAMEs, and shows linearity over a wide range of con-
centrations [18]. In this particular experiment, the
dynamic range stretched from 0.15% to 40%. The response
for the 37 FAME components showed good linearity (all
R2 values between 0.991 and 1.00) (see Additional file 1,
Table S2). The long-term inter-instrument precisions
(%CV) of the 37 FAME standards have been validated by
daily monitoring of two different levels of calibration stan-
dards analyzed on three different instruments between
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Figure 1 Accuracy and precision of the automated sample-preparation method compared with the conventional manual method.
(a) Correlation of mean values (%) of 19 fatty acids (Table S1) measured by conventional (n = 26) and automated (n = 26) methods.
(b) Scatterplot of the fatty-acid average against the standard deviation for both methods, showing the differences in precision (n = 26 both
groups; based on Van Batenburg et al. [23]).
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56 runs, shown in Supporting Information (see Additional
file 1, Table S2). The detection limits from 0.3 to 1.8 ng
per injection for the 37 FAMEs were calculated (see Addi-
tional file 1, Table S2), based on a signal-to-noise ratio of
3:1. The limit of quantification (LOQ) for plasma samples
with a volume of 125 μl (2 μl GC injection) or 250 μl (1 μl
GC injection) were also calculated (see Additional file 1,
Table S2). The 250 μl volume was selected for routine ana-
lysis of plasma samples and the 125 μl volume was used
when repeats were required.
The analytical accuracy and intra-assay %CV within
batches were examined by analyzing the six plasma repli-
cates (250 μl) spiked with known concentrations of C15:0
(330 μmol/l) and cis C18:2n6 (570 μmol/l) phosphatidyl-
cholines. The recoveries ranged from 77.1% to 89.3% with
a %CV of 5.5 for C15:0, and from 83.3% to 100.8% with
a %CV of 10.0 for cis C18:2n6 (for detailed results, see
Additional file 1, Table S3).
Not all of the 37 fatty acids were present in the QC
material at sufficient levels to be reproducibly measured
(Table 2). All fatty acids present at levels of less than
0.15% showed insufficient reproducibility (CV > 20%). The
precision for these low-level fatty acids was not an issue,
as the standards mixture held sufficient amounts of these
fatty acids for reproducibility to be satisfactory (CV < 5%).
As a general rule, all measurements with a level of less
than 0.15% were assessed as being below LOQ. Although
a splitless injection could have increased the LOQ, it
would also have decreased the throughput because it
would have required a different temperature program to
ensure adequate resolution of the solvent peak from the
shorter-chain FAMES.
Internal quality control in routine analysis
Analysis of this very large sample set took place over
several months. It required a rigorous internal QC (IQC)
system to ensure that the measured fatty-acid results were
reliable and that data across the whole study were compar-
able. IQC was conducted by inserting QC1 and QC2
materials into each batch of analysis. After preliminary
replicated QC1 and QC2 results in 60 successive batches
were collected, the estimated mean and SD between
batches were used to build the QC charts for each of the
fatty-acid components. The QC1 and QC2 materials were
successively analyzed daily over a 20-month period. The
QC1 and QC2 measurements within these 860 batches
were obtained from three parallel automated systems.
Shewhart control charts were used [19], which include an
average line (Avg), a lower control limit (LCL) and an
upper control limit (UCL) to determine if data obtained
within a batch were comparable with previously obtained
data. An example of the Shewhart control chart with indi-
vidual measurements of DHA (C22:6n3) and EPA (20:5n3)
in human plasma (QC1) is shown in Figure 2. There were
no batches for which the obtained data were outside
the QC limits for either the DHA or EPA results over
860 batches. The long-term reproducibility and stability of
the control materials were verified over a period of 20
months and presented as %CV. For instance, over 860
analyses of the human plasma QC1 sample, the mean
DHA percentage was 2.15% with CV = 2.8%, and the
mean EPA percentage was 0.47% with a CV = 6.8%. These
DHA and EPA results were divided into 10 monthly
subgroups. The monthly means were compared bysingle-
factor ANOVA (Table 1). There were no statistically sig-
nificant differences (all P > 0.05) between the monthly
means, and no evidence for any trend towards difference
over a period of 10 months for both DHA and EPA mea-
sured in human plasma QC1.
Throughput and speed
The aim of automating the method was not only to
improve analytical precision, but more importantly to
increase throughput and reliability, and to reduce the
cost per sample. Analysis of fatty acids from the different
fractions of human biological fluids is a laborious task. In
previous projects, in which sample sets were analyzed
using conventional manual methods, it was found that a
team of two people could maintain a throughput of
around 300 to 350 real samples per month. With the
automated method running on three parallel systems, we
achieved an average throughput of approximately 1,200
samples per month (including maintenance of the
system, and reanalysis of failed samples). To run and
maintain these three systems and cover all aspects
from sample reception to manual checking of the chro-
matograms, we need a team of at least four people.
This means that the actual throughput per person
doubled by changing to the automated method, which
significantly reduced the cost per sample. The systems
proved to be adequately reliable in a research environ-
ment, with very limited downtime (less than 10%) and
limited error rate (in almost all cases, the sample or
extract could be recovered and useful results could be
obtained after diagnosis of the reason for failure, modifi-
cation of the method to accommodate the failure, and
repeat analysis). However, the systems demanded con-
stant preventive maintenance to maintain this level of
reliability. As a result, the cost of spares for the sample-
automation robotics was a significant contributor to the
cost of ownership of this equipment. Nevertheless, this
throughput allowed us to analyze 860 batches covering
over 20,000 samples in 24 months.
Conclusion
We have developed a convenient, high-throughput
determination of phospholipid fatty acids, using a robot-
based automated system combined with GC. Use of this
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method resulted in the reduction of the analytical bur-
den and time. This method promises significant advan-
tages for completing large sample numbers in major
epidemiological studies.
Three parallel automated systems, which have proved to
be both robust and user-friendly, are currently performing
analysis of 90 samples plus standards and QC samples per
day. The analytical method described here has sufficient
reproducibility and long-term stability to be suitable for
fatty-acid determination in plasma phospholipids for both
epidemiological research studies and routine analysis.
Furthermore, this method can easily be adapted to other
samples, such as cell extracts, tissue homogenates, and
food samples.
Methods
Equipment
Sequential multipurpose sampler (MPS) systems (Gerstel
GmbH & Co. KG, Mülheim an der Ruhr, Germany) were
used for sample preparation, subsequent phospholipid
hydrolysis, FAME production, and injection of the sam-
ple into the GC for chromatographic analysis. The MPS
systems were equipped with appropriately sized motor-
ized syringes and accessories suitable for the tasks to be
performed. The function of the MPS systems was con-
trolled either by stand-alone Maestro software (Gerstel
GmbH & Co. KG) for sample extraction and solid-phase
cleanup, or Maestro software integrated within Agilent
ChemStation software (Agilent Technologies, Inc.,
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Figure 2 The Shewhart quality control (QC) chart of 20-month individual measurements for phospholipid docosahexaenoic acid (DHA)
(C(22,6n3)) and eicosapentaenoic acid (EPA) ((C(20,5n3)) in the QC material (QC1).
Table 1 Comparison of the monthly mean percentages of
the docosahexanomic acid (DHA) and eicosapentaenoic
acid (EPA) profiles.
Months DHA EPA
Mean SD %CVa Mean SD %CV
1 (n = 36)b 2.14 0.06 2.60 0.46 0.02 4.22
2 (n = 36) 2.14 0.06 2.66 0.46 0.01 2.22
3 (n = 38) 2.13 0.06 3.02 0.47 0.03 7.28
4 (n = 38) 2.15 0.08 3.58 0.47 0.04 9.16
5 (n = 37) 2.16 0.06 2.66 0.47 0.03 7.13
6 (n = 38) 2.15 0.05 2.47 0.48 0.04 8.46
7 (n = 38) 2.16 0.04 1.78 0.47 0.03 6.54
8 (n = 38) 2.15 0.07 3.23 0.47 0.02 5.30
9 (n = 38) 2.15 0.06 2.71 0.46 0.03 6.90
10 (n = 38) 2.17 0.05 2.55 0.46 0.03 6.31
Comparisons of meansc P = 0.062 P = 0.064
aCoefficient of variation.
bn is the number of batches in the month.
cSingle-factoR ANOVA.
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Wilmington, DE, USA) for FAME preparation and subse-
quent analysis. GC analysis was performed using a gas
chromatograph (7890N; Agilent Technologies), equipped
with an FID and split/splitless injector system. The
separation was performed on a capillary column 30 m in
length, with internal diameter of 0.25 mm, and film
thickness of 0.2 μm (J&W HP-88; Agilent Technologies).
A multi-tube vortexer (IKA Werke Gmbh & Co KG,
Staufen Germany) and a refrigerated centrifuge (MSE
Ltd, London, UK) were used for the manual liquid-liquid
Table 2 Measured levels of all fatty acids across 860 batches analyzed on three independent systems.
Fatty acid Mix Std1a QC1b QC2c
Meand SDe CVf Meand SDe CVf Meand SDe CVf
C8:0 Caprylic 2.61 0.14 5.36 NDg - - NDg - -
C10:0 Capric 3.72 0.15 4.12 0.01 BLOQh - 0.01 BLOQh -
C11:0 Undecanoic 2.01 0.07 3.50 ND - - 0.01 BLOQ -
C12:0 Lauric 4.21 0.13 3.13 0.02 BLOQ - 0.01 BLOQ -
C13:0 Tridecanoic 2.19 0.06 2.82 0.02 BLOQ - 0.11 BLOQ -
C14:0 Myristic 4.41 0.10 2.35 0.25 0.04 15.90 0.18 0.04 21.60
C14:1 Myristoleic 2.16 0.06 2.69 ND - - ND - -
C15:0 Pentadecanoic 2.23 0.05 2.06 0.16 0.03 16.07 0.13 BLOQ -
C15:1 Pentadecenoic 2.16 0.05 2.35 ND - - 0.01 BLOQ -
C16:0 Palmitic 6.65 0.19 2.89 30.12 0.43 1.43 15.02 0.35 2.30
C16:1 Palmitoleic 2.04 0.04 2.13 0.36 0.03 8.53 0.33 0.03 8.55
C17:0 Heptadecanoic 2.12 0.06 2.90 0.41 0.03 7.23 0.68 0.04 5.46
C17:1 Heptadecenoic 2.22 0.04 2.02 0.07 BLOQ - 0.11 BLOQ -
C18:0 Stearic 4.40 0.13 3.01 16.18 0.31 1.89 30.53 0.31 1.02
C18:1n9t Trans-oleic 2.18 0.04 1.91 0.20 0.04 19.96 0.08 BLOQ -
C18:1n9c Cis-oleic 4.36 0.09 1.97 8.24 0.19 2.30 9.05 0.15 1.65
C18:2n6t Trans-linoleic 2.10 0.05 2.26 0.06 BLOQ - 0.35 0.07 19.11
C18:2n6c Cis-linoleic 2.19 0.04 1.96 22.79 0.24 1.04 38.07 0.46 1.20
C18:3n6 g-Linoleic 2.11 0.04 2.13 0.06 BLOQ - ND - -
C18:3n3 a-Linoleic 2.17 0.05 2.18 0.25 0.09 37.65 1.68 0.24 14.24
C20:0 Arachidic 4.39 0.15 3.38 0.14 0.02 17.80 0.70 0.07 9.69
C20:1 Eicosenoic 2.11 0.05 2.26 0.19 0.04 19.57 0.38 0.04 11.53
C20:2 Eicosadienoic 2.12 0.05 2.38 0.39 0.02 4.63 0.25 0.02 9.82
C20:3n6 Dihomo-g-linoleic 2.08 0.06 2.95 3.45 0.09 2.67 0.41 0.05 12.66
C20:4n6 Arachidonic 4.02 0.09 2.22 11.15 0.19 1.67 0.98 0.05 5.57
C20:5n3 Eicosapentaenoic 2.13 0.09 4.26 0.47 0.03 7.20 0.20 0.04 18.48
C21:0 Heneicosanoic 2.17 0.08 3.70 ND - - 0.01 BLOQ -
C22:0 Behenic 4.32 0.18 4.19 0.26 0.03 13.02 0.09 BLOQ -
C22:1n9 Erucic 2.09 0.06 2.73 0.02 BLOQ - 0.01 BLOQ -
C22:2 Brassic 2.09 0.09 4.13 ND - - 0.02 BLOQ -
C22:4 Adrenic 1.77 0.06 3.60 0.51 0.02 4.60 ND - -
C22:5n6 Osbond 0.00 0.00 0.00 0.32 0.03 9.24 0.01 BLOQ -
C22:5n3 Docosapentaenoic 1.88 0.08 4.20 0.89 0.06 6.53 0.21 0.03 15.68
C22:6n3 Docosahexaenoic 1.79 0.05 2.90 2.20 0.09 4.05 0.11 BLOQ -
C23:0 Tricosanoic 2.15 0.09 4.35 0.11 BLOQ - 0.03 BLOQ -
C24:0 Lignoceric 4.30 0.20 4.57 0.27 0.03 10.47 0.13 BLOQ -
C24:1 Nervonic 2.13 0.07 3.16 0.36 0.04 12.31 0.17 0.03 18.32
aMixture of fatty-acid methyl ester standards; fresh batches of mixtures were prepared every 1 to 2 months, and mean values were calculated for each batch (see
Methods section).
bNormal pooled human plasma (PLH-123-F; Sera Laboratories International).
cNormal pooled horse plasma (S-121-F; Sera Laboratories International).
dMean level determined over 860 batches using three independent systems.
eStandard deviation determined over 860 batches using three independent systems.
fCoefficient of variation (100% × SD/mean).
gNot detected (level below 0.01%).
hBelow limit of quantification (level below 0.15%). Mean values are given, but precision is insufficient.
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extraction. A vacuum manifold was used to assist the
manual SPE, and a vacuum evaporator (AES2010; Savant
Instruments Inc., Holbrook, NY, USA) was used to eva-
porate the solvents for the conventional method.
Chemicals, standards, and QC samples
We used analytical reagent-grade chemicals and solvents:
sodium chloride, chloroform, n-hexane, and 14% boron
trifluoride (BF3)/methanol solution (Sigma-Aldrich,, St
Louis, MO, USA). Methanol and acetone were HPLC
grade (Thermo Fisher Scientific Inc., Rockford, IL, USA).
All FAME standards (for complete list of fatty acids ana-
lyzed with full IUPAC names, see Additional file 1, Table
S2) were were commercial grade (Supelco, Bellefonte,
PA, USA). Aminopropylsilica 100 mg SPE cartridges
(BondElut; Agilent Technologies) were used for the con-
ventional method and Na2SO4 50 mg/NH2 100 mg SPE
cartridges (BE Gerstel; Agilent Technologies) were used
for the automated method. The QC samples used in this
study were QC1, which was normal human plasma
(mixed gender, pooled; PLH-123-F; Sera Laboratories
International Ltd, Haywards Heath, West Sussex, UK)
and QC2, which was normal pooled horse plasma (S-
121-F; Sera Laboratories International). The QC1 sample
was chosen to represent the samples of the application
study [17], while the QC2 sample was chosen to be sig-
nificantly different from QC1.
Preparation of standards and QC materials
A series of working standards containing 37 FAMEs were
prepared by accurately transferring 0.01, 0.05, 0.1, 0.5,
and 1.0 ml each of the following individual standards and
mixture of standards to glass vials: 37 mix FAME stan-
dard (47885-U; Supelco), C22:5n3 FAME (0.6 mmol/l),
C22:4 FAME (0.75 mmol/l) and C22:5n6 FAME (0.6
mmol/l). C4:0 and C6:0 FAMEs presented in the mixture
of 37 FAME standards overlapped with the solvent peak,
and C22:3n3 and C20:4n6 did not separate under the
chromatographic conditions used, leaving 37 FAMEs for
quantification. The contents of the vials were evaporated
to dryness under a stream of nitrogen, and then reconsti-
tuted in n-hexane (1 ml) to yield a series of the 37 FAME
mixtures as the standards for GC calibration (for the
complete list of all 37 fatty acids analyzed, see Additional
file 1, Table S2).
Sufficient volumes of each QC material were homoge-
nized, and aliquots of QC materials were transferred
into cryo-tubes and stored at -80°C before analysis. QC1
and QC2 samples were analyzed in each batch to moni-
tor inter-assay variation.
Sample preparation
The Folch extraction for total lipids [20] and the isola-
tion of phospholipid fraction (based on Burdge et al.
[21]), performed by both the conventional and auto-
mated methods, are described below.
Conventional manual sample extraction and SPE method
Aliquots of thawed plasma and QC samples (125 or 250
μl) were transferred to disposable glass tubes (16 × 100
mm). All sample volumes were made up to 0.5 ml with
saline (0.9% w/v), then 1.0 ml methanol and 2.0 ml chloro-
form were added to extract total lipids from samples. The
tubes were placed in a multi-tube vortex mixer, and mixed
for 10 minutes at 1,200 rpm. Following this, 0.5 mlsodium
chloride solution (1 mol/l) was added to the sample
mixture, which was mixed by vortex for a further 2
minutes at 1200 rpm. Subsequent centrifugation at 2,500
rpm (1000 g) for 10 minutes was used to separate the
organic and aqueous phases. The bottom chloroform layer
was quantitatively transferred to another disposable glass
tube (11 × 75 mm), then the tubes were placed in a
vacuum evaporator for 45 minutes at 40°C to evaporate
the solvent to near dryness.
Total lipid extract was dissolved in1.0 ml dry chloro-
form, and mixed by vortex. The sample was loaded on to
a 1 ml aminopropyl SPE cartridge and allowed to slowly
pass through the cartridge under gravity. Once the liquid
meniscus reached the top of the SPE cartridge, the
remaining liquid in the adsorbent bed was removed
under vacuum. The SPE cartridge was then washed
under vacuum with 2.0 ml chloroform. The phospholipid
fraction was eluted into a 4 ml sample-collection vial
with 2.0 ml of methanol chloroform (40:60 v/v) under
vacuum, and the eluate was evaporated to dryness in a
vacuum evaporator at 40 C. The 4 ml vials were capped
and stored at -20°C until required for derivatization and
analysis.
Automated sample extraction and SPE method
The automated sample extraction and SPE method was
constructed to replicate the existing manual method as
far as possible, within the limitations of the robotic sys-
tem,. The main limitation of the automated system was
the ability to control only a single syringe, which necessi-
tated extra syringe wash steps and the use of acetone as a
co-solvent when changing between immiscible solvents,
typically chloroform and water. In addition, vials of sizes
appropriate for the hardware and the liquid volumes
used at each stage were substituted for the disposable
glass tubes used in the manual method. The plasma, sal-
ine, and methanol/chloroform mixtures were prepared
off-line in 6 ml crimp-cap sealed vials. and the intermedi-
ate and finished products in 4 ml crimp-capped sealed
vials (Chromacol; Esslab UK, Hadleigh Essex, UK).
Set out below is a brief, step-by-step representation of
the automated SPE procedure using the MPS system
(numbers in brackets correspond to those in Figure 3a).
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1. Pipette 250 μl thawed plasma into a vial. Add 250 μl
0.9% saline, 1.0 ml methanol, and 2.0 ml chloroform,
then cap the vial. Repeat for 28 samples.
2. Pipette 500 μl 0.9% saline into a vial. Add 1.0 ml
methanol and 2.0 ml chloroform, then cap the vial. This
vial forms the process blank.
3. Pipette 250 μl thawed pooled human plasma into a
vial. Add 250 μl 0.9% saline, 1.0 ml methanol, and 2.0 ml
chloroform, then cap the vial. This vial is the QC1 sample.
4. Pipette 250 μl thawed horse plasma into a vial. Add
250 μl 0.9% saline, 1.0 ml methanol, and 2.0 ml chloro-
form, then cap the vial. This vial is the QC2 sample.
Figure 3 Multipurpose sampler (MPS) systems for automated sample preparation and derivatization of fatty acids of the phospholipid
fraction from human plasma samples. (a) MPS single beam for phospholipid extraction. 1) Solid-phase extraction (SPE) MPS Beam; 2) syringe holder;
3) 1 mol/l saline reservoir; 4) solvent reservoirs; 5) three-position tray holder, 6) SPE cartridge tray; 7) SPE/blowdown; 8) vortex/centrifuge. (b)) Dual-beam
MPS system for phospholipid hydrolysis, derivatization and injection. 1) Derivatization MPS beam; 2) derivatization syringe holder; 3) injection MPS beam;
4) injection syringe holder; 5) heated zone; 6) wash vials; 7) SPE/blowdown; 8) solvent reservoirs; 9) four-position tray holder; 10) agitator.
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5. Shake all vials for 10 minutes in an orbital shaker [8].
6. Add 500 μl saline 1 mol/l by [2] from [3].
7. Shake for 30 seconds on [8].
8. Centrifuge at 2,700 rpm (500 g) for 5 minutes to
promote phase separation on [8].
9. Aspirate 1,600 μl of the lower chloroform layer, and
transfer to a clean vial by [2] from [4].
10. Dry the crude extract under a stream of nitrogen at
55°C on [7].
11. Reconstitute the crude extract in 2.0 ml dry
chloroform by [2] from [4].
12. Pass the crude extract through a 1 ml aminopropyl
silica cartridge on [7].
13. Wash the cartridge with 2.0 ml dry chloroform by
[2] from [4].
14. Remove excess solvent from the sorbent bed by
flushing with 4 × 2.5 ml aliquots of air on [7].
15. Elute the plasma-phospholipid fraction using 2.0
ml methanol/chloroform 40% v/v by [2] from [4].
16. Recover remaining elution solvent from the sorbent
bed by flushing with 4 × 2.5 ml aliquots of air by [2] from
[4].
17. Blow the phospholipid fraction dry under a stream
of nitrogen at 55°C on [7].
18. Store the vials containing the phospholipid fraction
at -20°C until required.
A schematic diagram of the timeline of the SPE analy-
sis is shown (see Additional file 1, Figure S4).
Automated preparation of FAME derivatives and GC
analysis
A dual-rail preparation station (Gerstel MPS Prepstation;
Gerstel GmbH & Co. KG) was located on a GC (7890N;
Agilent Technologies). The lower rail was configured to
perform the on-line phospholipid hydrolysis and FAME-
derivative preparation, and the upper rail was configured
to perform sample injection. For each experiment, 32 vials
(4 ml each; comprising 29 dried phospholipid extracts,
process blank, QC1 & QC2) were manually loaded on
the Gerstel automation platform. Derivatization reagent
(500 μl of 14% BF3/methanol solution), which both hydro-
lyses the phospholipids and forms the methyl esters of the
liberated fatty acids, was added to the vials. The vials were
incubated at 75°C for 45 minutes to yield the crude FAME
derivatives. After the addition of 1 ml hexane to extract
the FAMEs and 1 ml water to decompose any unreacted
boron trifluoride and to scavenge any polar impurities, the
vial was shaken to complete the FAME extraction. A por-
tion (600 μL) of the upper hexane layer was transferred to
a 1.5 ml high-recovery GC vial and evaporated to dryness.
FAMEs were reconstituted in hexane 100 μL as the final
sample solution. A 1 μL aliquot of this sample solutionwas
injected into the GC split injector (split ratio 20:1) for GC
analysis, using the following conditions: helium carrier
1.5 ml/min, oven temperature profile initially 120°C for
1 minute, then ramped to 170°C at 10°C/min, held for
6 minutes, and finally raised to 210°C at a rate of 3°C/min
and held for 1 minute. The injector temperature was
maintained at 250°C and the detector temperature main-
tained at 300°C. A post-run period (235°C for 3.5 minutes
at 2.5 ml/min) was used to eliminate possible interfer-
ences. The total run time was approximately 30 minutes.
Separation of the 37 FAME standards was carried out
using a GC capillary column (HP-88; Agilent Technolo-
gies). In the chromatogram, all compounds in the standard
mixture were well resolved (see Additional file 1,
Figure S1) with the exception of C20:3n3 and C20:4n6,
which co-eluted, however, the level of C20:3n3 in human
samples is negligible, and therefore we annotated this peak
as C20:4n6 [22]. A representative plasma chromatogram
separated on the HP88 column (see Additional file 1,
Figure S2) showed that the cis/trans isomers and highly
unsaturated fatty-acid mixtures were fully separated from
the sample. A process blank chromatogram (see Additional
file 1, Figure S3) was used to monitor any fatty acids con-
tamination from chemicals, glassware, and the sample-pre-
paration process. The process blank values (mainly trace
levels of C14:0, C16:0, and C18:0) were deducted from the
calculation of the plasma phospholipid fatty-acid results.
Data collection and integration were performed with Agi-
lent ChemStation software on a desktop computer.
Set out below is a brief, step-by-step representation of
sample hydrolysis and derivatization by the automated
method using the MPS dual-beam system (numbers in
brackets correspond to Figure 1b).
1. Add 500 μl 14% BF3/MeOH solution to a vial con-
taining the dried phospholipid fraction by [2] from [8].
2. Transfer vial to heated zone at 75°C and allow to
react for 45 minutes [5].
3. Remove vial from heated zone and allow to cool to
room temperature [9].
4. Add 1 ml hexane and 1 ml water by [2] from [8].
5. Shake for 5 minutes [10].
6. Stand for 2 minutes to allow phases to separate [9].
7. Remove 600 μl of the hexane layer containing the
FAMEs, and transfer to a vial from which the injection
is to be made by [2] from [8].
8. Dry the FAME extract under a stream of nitrogen
at 35°C [7].
9. Reconstitute the extract in 100 μl hexane by [2]
from [8].
10. Inject sample into GC by [4].
A schematic diagram of the timeline of sample hydrolysis
and derivatization is shown (see Additional file 1, Figure S5).
Identification and quantifiation
FAMEs in the samples were identified by comparison of
their retention times with those of individual FAME
Wang et al. Genome Medicine 2013, 5:39
http://genomemedicine.com/content/5/4/39
Page 9 of 11
standards. The palmitic acid methyl ester (C16:0) was
used as a reference FAME. We measured the relative
quantities of the 37 fatty acids, with each of the 37 ana-
lytes being measured as a percentage of the total fatty-
acid signal.
Statistical analysis
Linear regression, mean, and SD were calculated(Excel™
2010; Microsoft Corp., Redmond, WA, USA). The precision
of the assay was defined as the CV of at least six repeats of
the QC sample across as many batches. For direct compari-
son, the Student’s t-test was used. Single-factor ANOVA)
was used for comparing more than two mean values.
Additional material
Additional File 1: Supplementary tables and figures: Table S1: Fatty-
acid profiles (%) of phospholipids in a quality control (QC2) sample,
comparing conventional manual versus automated sample-preparation
methods. Table S2: Instrumental validation using a fatty-acid methyl ester
(FAME) standard mixture. Table S3: Recovery evaluation of human
plasmas spiked with tknown phospholipids (C15:0 and cis-C18:2n6).
Figure S1: A mixture standard of FAMEs separated on the HP88 column.
Figure S2: A representative plasma chromatogram separated on the
HP88 column. Figure S3: A reagent blank chromatogram separated on
the HP88 column. Figure S4: SPE Timeline graphics. Figure S5:
Derivatization and gas chromatography (GC) run timeline.
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